Your browser doesn't support javascript.
loading
A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors.
Kasuga, Akiyoshi; Nakagawa, Kazuhiko; Nagashima, Fumio; Shimizu, Toshio; Naruge, Daisuke; Nishina, Shinichi; Kitamura, Hiroshi; Kurata, Takayasu; Takasu, Atsuko; Fujisaka, Yasuhito; Okamoto, Wataru; Nishimura, Yuichiro; Mukaiyama, Akihira; Matsushita, Hideki; Furuse, Junji.
Afiliación
  • Kasuga A; Department of Medical Oncology, Kyorin University Hospital, 6-20-2 Shinkawa, 181-8611, Mitaka, Tokyo, Japan.
  • Nakagawa K; Department of Medical Oncology, Faculty of Medicine, Kinki University Hospital, 377-2, Ono-Higashi, 577-0818, Osakasayama City, Osaka, Japan.
  • Nagashima F; Department of Medical Oncology, Kyorin University Hospital, 6-20-2 Shinkawa, 181-8611, Mitaka, Tokyo, Japan.
  • Shimizu T; Department of Medical Oncology, Faculty of Medicine, Kinki University Hospital, 377-2, Ono-Higashi, 577-0818, Osakasayama City, Osaka, Japan.
  • Naruge D; Department of Medical Oncology, Kyorin University Hospital, 6-20-2 Shinkawa, 181-8611, Mitaka, Tokyo, Japan.
  • Nishina S; Department of Medical Oncology, Faculty of Medicine, Kinki University Hospital, 377-2, Ono-Higashi, 577-0818, Osakasayama City, Osaka, Japan.
  • Kitamura H; Department of Medical Oncology, Kyorin University Hospital, 6-20-2 Shinkawa, 181-8611, Mitaka, Tokyo, Japan.
  • Kurata T; Department of Medical Oncology, Faculty of Medicine, Kinki University Hospital, 377-2, Ono-Higashi, 577-0818, Osakasayama City, Osaka, Japan.
  • Takasu A; Department of Medical Oncology, Kyorin University Hospital, 6-20-2 Shinkawa, 181-8611, Mitaka, Tokyo, Japan.
  • Fujisaka Y; Department of Medical Oncology, Faculty of Medicine, Kinki University Hospital, 377-2, Ono-Higashi, 577-0818, Osakasayama City, Osaka, Japan.
  • Okamoto W; Department of Medical Oncology, Faculty of Medicine, Kinki University Hospital, 377-2, Ono-Higashi, 577-0818, Osakasayama City, Osaka, Japan.
  • Nishimura Y; Medicines Development, Oncology Therapeutic Area, GlaxoSmithKline K.K., 6-15, Sendagaya 4-chome, 151-8566, Tokyo, Japan.
  • Mukaiyama A; Medicines Development, Oncology Therapeutic Area, GlaxoSmithKline K.K., 6-15, Sendagaya 4-chome, 151-8566, Tokyo, Japan.
  • Matsushita H; Medicines Development, Oncology Therapeutic Area, GlaxoSmithKline K.K., 6-15, Sendagaya 4-chome, 151-8566, Tokyo, Japan.
  • Furuse J; Department of Medical Oncology, Kyorin University Hospital, 6-20-2 Shinkawa, 181-8611, Mitaka, Tokyo, Japan. jfuruse@ks.kyorin-u.ac.jp.
Invest New Drugs ; 33(5): 1058-67, 2015 Oct.
Article en En | MEDLINE | ID: mdl-26259955
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Piridonas / Pirimidinonas / Desoxicitidina / Neoplasias / Antineoplásicos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Invest New Drugs Año: 2015 Tipo del documento: Article País de afiliación: Japón
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Piridonas / Pirimidinonas / Desoxicitidina / Neoplasias / Antineoplásicos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Invest New Drugs Año: 2015 Tipo del documento: Article País de afiliación: Japón